UPDATE: JPMorgan Upgrades Sarepta Therapeutics (SRPT) to Overweight
Tweet Send to a Friend
(Updated - November 5, 2021 4:19 AM EDT)
JPMorgan analyst Anupam Rama upgraded Sarepta Therapeutics (NASDAQ: SRPT) from Neutral ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
JPMorgan analyst Anupam Rama upgraded Sarepta Therapeutics (NASDAQ: SRPT) from Neutral ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
